Compare PTY & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTY | WGS |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | 2002 | 2020 |
| Metric | PTY | WGS |
|---|---|---|
| Price | $11.01 | $70.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $90.44 |
| AVG Volume (30 Days) | ★ 1.7M | 645.5K |
| Earning Date | 01-01-0001 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $427,539,000.00 |
| Revenue This Year | N/A | $12.70 |
| Revenue Next Year | N/A | $24.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.97 |
| 52 Week Low | $10.65 | $32.21 |
| 52 Week High | $14.69 | $170.87 |
| Indicator | PTY | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 37.74 | 36.98 |
| Support Level | N/A | $71.85 |
| Resistance Level | $11.92 | $94.82 |
| Average True Range (ATR) | 0.20 | 6.64 |
| MACD | -0.02 | -3.00 |
| Stochastic Oscillator | 38.79 | 4.57 |
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on both public or private basis.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.